Loading financial data...

Barinthus Biotherapeutics plc. (BRNS) Financial Statements | Global Financial Data

Barinthus Biotherapeutics plc.

BRNSSEC EDGAR

Pharmaceutical Preparations(X0)CIK: 1828185

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$15.0M	$802.0K	$44.7M	$268.0K	$4.8M
Research and Development Expense	$42.2M	$44.9M	$42.4M	$20.4M	$14.4M
Operating Expenses	$84.1M	$84.7M	$48.7M	$45.5M	$24.9M
Operating Income (Loss)	-$68.0M	-$83.9M	-$4.0M	-$45.2M	-$20.0M
Interest Expense	—	—	$19.0K	$2.7M	$3.6M
Nonoperating Income (Expense)	$6.7M	$7.4M	$4.9M	-$5.9M	$2.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$61.2M	-$76.5M	$850.0K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$160.3M	$214.5M	$270.2M	$280.7M	$50.7M
Assets, Current	$125.7M	$156.9M	$213.0M	$226.8M	$47.9M
Cash and Cash Equivalents, at Carrying Value	$110.7M	$142.1M	$194.4M	$214.1M	$43.3M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	$20.0K	$518.0K
Liabilities	$30.2M	$27.5M	$27.0M	$28.2M	$53.8M
Liabilities, Current	$15.7M	$12.6M	$12.2M	$11.2M	$7.6M
Accounts Payable, Current	$2.5M	$1.6M	$3.7M	$2.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$28.9M	-$50.9M	-$14.4M	-$32.6M	-$11.0M
Net Cash Provided by (Used in) Investing Activities	-$892.0K	-$5.4M	-$5.8M	-$12.9M	-$293.0K
Net Cash Provided by (Used in) Financing Activities	$2.2M	$1.9M	$325.0K	$222.7M	$41.4M
Payments to Acquire Property, Plant, and Equipment	$892.0K	$5.4M	$6.1M	$1.1M	$293.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)